OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody.
Chatenoud
L
L
Inserm U25, Hôpital Necker, Paris, France.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D051379:Mice; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity*; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000502:physiology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha